1
|
A novel Mutein of TNFalpha Containing the Arg-Gly-Asp Sequence Shows Reduced Toxicity in Intestine. Mediators Inflamm 2012; 3:111-6. [PMID: 18472928 PMCID: PMC2367030 DOI: 10.1155/s096293519400013x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
The effects of human tumour necrosis factor-α (TNFα), or its
mutein (F4168) having the cell adhesive Arg-Gly-Asp sequence at the
N-terminus, on intestinal injury, were examined. Histopathological
examination revealed that an intravenous injection of TNFα
resulted in marked haemorrhage or oedema in the caecum of rats,
whereas F4168 showed no such effects even at the same therapeutic
dose. Moreover, the number of neutrophils that adhered to
endothelial cells or infiltrated the mucosal tissue was much higher
after TNFα injection compared with F4168 in vivo.
The enhanced adhesion of neutrophils on to human umbilical vein
endothelial cells also occurred when the latter were pre-stimulated
with TNFα but not with F4168 in vitro. The
expression of the cell adhesion molecules including endothelial
leukocyte adhesion molecule-1 or intercellular adhesion molecule-1
on F4168- stimulated human umbilical vein endothelial ceils was
significantly lower than that stimulated with TNFα. These
results suggest that the Arg-Gly-Asp sequence introduced into the
TNFα molecule abrogates the side effect of this cytokine such
as tissue injury or shock, and that F4168 could be useful for
systemic therapy.
Collapse
|
2
|
Wang H, Yan Z, Shi J, Han W, Zhang Y. Expression, purification, and characterization of a neovasculature targeted rmhTNF-alpha in Escherichia coli. Protein Expr Purif 2005; 45:60-5. [PMID: 16027006 DOI: 10.1016/j.pep.2005.05.009] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2005] [Revised: 05/08/2005] [Accepted: 05/18/2005] [Indexed: 11/22/2022]
Abstract
The tumor vasculature is a suitable target for cancer treatment. RGD-4C (CDCRGDCFC) peptide can bind to human alphav integrins, which are known to be selectively expressed in human tumor blood vessels. Some studies showed that coupling anticancer drugs or peptides to the RGD peptides yielded compounds with increased efficacy against tumors and lowered toxicity to normal tissues in mice. TNF-alpha mutant (rmhTNF-alpha) that we previously constructed has been proved to have stronger antitumor effect compared with TNF-alpha. To increase antitumor effect and lower toxicity of rmhTNF-alpha, we coupled RGD4C to the N-terminal of rmhTNF-alpha (termed RGD4C-rmhTNF) and expressed RGD4C-rmhTNF in Escherichia coli. Here, we describe the expression, purification, and characterization of RGD4C-rmhTNF.
Collapse
Affiliation(s)
- Hui Wang
- Biotechnology Center of The Fourth Military Medical University, 17 Changle West Road, 710032 Xi'an, PR China
| | | | | | | | | |
Collapse
|
3
|
Kuroda K, Miyata K, Fujita F, Koike M, Fujita M, Nomura M, Nakagawa S, Tsutsumi Y, Kawagoe T, Mitsuishi Y, Mayumi T. Human tumor necrosis factor-alpha mutant RGD-V29 (F4614) shows potent antitumor activity and reduced toxicity against human tumor xenografted nude mice. Cancer Lett 2000; 159:33-41. [PMID: 10974403 DOI: 10.1016/s0304-3835(00)00529-2] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
The antitumor effects of human tumor necrosis factor-alpha (TNF) mutant RGD-V29 (code no. F4614), that includes the cell adhesive sequence (4)Arg-(5)Gly-(6)Asp and (29)Arg-->Val substitution, were evaluated. The therapeutic index, a measure of the extent of the therapeutically-effective range, using three constitutive administrations of RGD-V29 in Meth A-bearing mice was 4.8, whereas that of recombinant human TNF (rhTNF) ((1)SSS(4)RTPSDK...(29)RR...(155)L) was 2.8, clearly indicating that the effective RGD-V29 dose-range was extended. Furthermore, RGD-V29 showed potent antitumor activity against human lung cancer Mqnu-1 xenografted nude mice without severe gastrointestinal and other organ toxicities, even when administered at the maximal tolerated dose (MTD). In contrast, rhTNF induced severe toxicity at the MTD. Direct cytotoxicity of RGD-V29 against Mqnu-1 cells was similar to that of rhTNF. In addition, a cytotoxicity assay using a tumor-derived endothelial-like cell (tEC)/normal endothelial cell (nEC) system used to study TNF antitumor effects on tumor-associated endothelial cells, suggested that RGD-V29 showed preferential cytotoxicity toward tumor-associated endothelial cells compared with rhTNF. Thus, RGD-V29 appears to be a low-toxicity mutant of rhTNF that shows preferential activity towards tumors, and therefore merits further investigation in pre-clinical and clinical studies.
Collapse
Affiliation(s)
- K Kuroda
- Medicinal Research Laboratory, Central Research Institute, Ishihara Sangyo Kaisha Ltd., 2-3-1 Nishi-Shibukawa, Kusatsu, 525-0025, Shiga, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Kuroda K, Miyata K, Tsutsumi Y, Tsunoda S, Nishimura K, Mitsuishi Y, Nakagawa S, Mayumi T. Preferential activity of wild-type and mutant tumor necrosis factor-alpha against tumor-derived endothelial-like cells. Jpn J Cancer Res 2000; 91:59-67. [PMID: 10744045 PMCID: PMC5926226 DOI: 10.1111/j.1349-7006.2000.tb00860.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Tumor-derived endothelial-like cells (tEC) were prepared by culturing human umbilical vein endothelial cells (HUVEC) in the presence of HT1080 human fibrosarcoma-conditioned medium. tEC showed higher permeability and less cell-adhesion activity than normal HUVEC (nEC). Tumor necrosis factor-alpha (TNF) is known to have tumor-vasculature disrupting activity. tEC showed higher cytotoxicity to recombinant human TNF (rhTNF) than nEC, and was not observed using HUVEC cultured with WI38 human diploid cell-conditioned medium as a medium-control. These results demonstrate that tEC acquire physiological properties of tumor-associated vasculature, and may be a useful model system for the study of the mechanisms of TNF antitumor action. The TNF-mutant RGD-V29 (code No. F4614), which has an inserted 4Arg-Gly-Asp sequence and an 29Arg-->Val replacement, was found to induce greater preferential destruction of tEC compared to rhTNF. When the preferential activities were evaluated in terms of 30% cytotoxicity (IC30) ratio (nEC/tEC), the ratio was 460 for RGD-V29 compared to 4.2 for rhTNF. RGD-V29 also exhibited cell-adhesive function and bound preferentially to the p55 TNF-receptor. Both these properties of RGD-V29 contributed to the tEC selective cytotoxicity, indicating that the RGD ligands and selective p55 receptor binding on the cells, although uncharacterized, are involved in tEC targeting. Therefore, the TNF mutant RGD-V29 may show greater selectivity toward tumor vasculature than wild-type TNF.
Collapse
Affiliation(s)
- K Kuroda
- Medicinal Research Laboratory, Central Research Institute, Ishihara Sangyo Kaisha, Ltd., Kusatsu, Shiga.
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Taniyama M, Morita T, Yamagishi Y, Kato A, Bando C, Okawa N, Kaji A. Human lymphotoxin mutein lacks hypotensive activity but has higher in vivo antitumor activity than lymphotoxin or tumor necrosis factor. Proc Natl Acad Sci U S A 1997; 94:3324-9. [PMID: 9096392 PMCID: PMC20368 DOI: 10.1073/pnas.94.7.3324] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
A serious drawback of tumor necrosis factor alpha (TNF) as a clinical antitumor agent is that it also has hypotensive activity. To overcome this problem, derivatives of its sister cytokine lymphotoxin (TNF-beta or LT) were prepared. One of them, mutein 2 (Mut2) has a deletion of amino acids 1-7 but contains substituted amino acids, Met-Phe-Pro at positions 8-10 of the mature human LT. This mutein has no hypotensive activity at the maximum dose (10 mg/kg) tested on rats. In contrast, a much lower dose (1 mg/kg) of TNF and LT caused a significant blood pressure drop. In vivo studies revealed that Mut2 was more effective than TNF or LT against MethA (a mouse tumor line) as judged by the therapeutic ratio [calculated as LD50 (dose that kills 50% of the animals)/ED50 (dose that reduces the tumor size by 50%)]. With five other different mouse tumors and two different human tumors, Mut2 was also effective and the effectiveness was comparable or superior to that of TNF or LT. These results suggest the possibility that this derivative may be usable as a clinical antitumor agent without the serious side effects associated with TNF.
Collapse
Affiliation(s)
- M Taniyama
- Tsumura Central Research Institute, Tsumura and Company, Inashiki-gun, Ibaraki, Japan
| | | | | | | | | | | | | |
Collapse
|
6
|
ten Hagen TL, Eggermont AM. A rat extremity soft tissue sarcoma model for the study of systemic treatment with Stealth® liposome-encapsulated tumor necrosis factor-α and cytotoxic agents. Adv Drug Deliv Rev 1997. [DOI: 10.1016/s0169-409x(96)00465-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
7
|
Abstract
Inflammatory mediators such as tumor necrosis factor (TNF) and interleukin-1 enhance tumor colony formation in different models of experimental and spontaneous metastasis. The involvement of the natural killer (NK) cell system in this process was investigated. Tumor necrosis factor does not appear to act directly on tumor cells by reducing their susceptibility to the cytotoxic action of NK cells but rather impairs NK activity in tumor-bearing mice. Such impairment of the natural killer system might be one means by which TNF supports tumor colony formation. Even though the metastasis- enhancing effect of TNF remained detectable in mice which have a greatly reduced NK cell cytotoxic activity due to a defect in the bg locus, normal mice which were depleted of NK cells by antibody treatment did not show enhanced metastasis after TNF injection. Therefore, the TNF-enhanced metastasis can only be seen as long as some NK cell function is operating in the animals.
Collapse
Affiliation(s)
- M Hafner
- Department of Pathology, Tumor Immunology, University of Regensburg, Germany
| | | | | | | |
Collapse
|
8
|
Giavazzi R. Cytokine-mediated tumor-endothelial cell interaction in metastasis. Curr Top Microbiol Immunol 1996; 213 ( Pt 2):13-30. [PMID: 9053288 DOI: 10.1007/978-3-642-61109-4_2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- R Giavazzi
- Mario Negri Institute for Pharmacological Research, Bergamo, Italy
| |
Collapse
|
9
|
Kuroda K, Miyata K, Shikama H, Kawagoe T, Nishimura K, Takeda K, Sakae N, Kato M. Novel muteins of human tumor necrosis factor with potent antitumor activity and less lethal toxicity in mice. Int J Cancer 1995; 63:152-7. [PMID: 7558445 DOI: 10.1002/ijc.2910630127] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Eight muteins of recombinant human tumor necrosis factor-alpha (rhTNF; 1SSSRTP...29RR...155L), in which 29Arg was replaced by another amino acid, were prepared and their anti-tumor effects in BALB/c mice bearing Meth A fibrosarcoma were evaluated. The therapeutic indices, which mark the extent of the therapeutically effective dose, of V29 (29Arg-->Val) and D29 (-->Asp) were 3.5 and 3.2, respectively, whereas that of rhTNF was 1.4. Clearly, the therapeutically effective range of these muteins was extended along with a decrease in lethal toxicity. V29 did not produce hypotension in the rat system, but D29 did. In addition, V29 showed potent anti-tumor activity (Tumor Volume Inhibition Rate = 81% on day 15 after implantation) in 3 consecutive injection schedules despite the decreases in toxicity compared with rhTNF. The relative receptor binding constant was determined using HEp-2 cells (expressing mainly 55-kDa-TNF receptor; p55R) and HL60 cells (expressing mainly 75-kDa-TNF receptor; p75R), and revealed that the reduced toxicity of V29 in mice was due to the reduced binding to p55R (34% of rhTNF). On the other hand, the ratio of the constants HEp-2/HL60 of V29 was 11 in comparison with the value of 1.0 for rhTNF, suggesting that this mutein binds preferentially to p55R. The biological activities in human cell lines (HEp-2 and HL60 cells) correlated well with the binding activities to each receptor in vitro. Therefore, the much lower toxicity and the potent anti-tumor activity of this mutein suggest that V29 merits further investigation in pre-clinical and clinical trials.
Collapse
Affiliation(s)
- K Kuroda
- Medicinal Research Laboratory, Ishihara Sangyo Kaisha, Ltd., Shiga, Japan
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Shikama H, Miyata K, Sakae N, Mitsuishi Y, Nishimura K, Kuroda K, Kato M. Novel mutein of tumor necrosis factor alpha (F4614) with reduced hypotensive effect. J Interferon Cytokine Res 1995; 15:677-84. [PMID: 8528939 DOI: 10.1089/jir.1995.15.677] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
To eliminate systemic toxicity, including the hypotension associated with human tumor necrosis factor alpha (TNF-alpha), we constructed mutant proteins (muteins) by mean of genetic engineering. A novel mutein, F4614, containing mutations of 5Thr-->Gly and 6Pro-->Asp, which resulted in the introduction of cell-adhesive Arg-Gly-Asp and 29Arg-->Val, had remarkably reduced hypotensive effects and lower lethality. We present evidence that the Arg-->Val mutation at position 29 is largely responsible for the reduced hypotensive effect. This effect of F4614 was thought to be closely correlated with its low inducibility of nitric oxide and prostaglandin E2 in vivo. In addition, the therapeutically effective dose of F4614 to MethA fibrosarcoma-transplanted mice was increased compared with that of TNF-alpha, indicating a wide therapeutic index. These results indicated that F4614 has several advantages as a systemic therapeutic drug in the treatment of cancer.
Collapse
Affiliation(s)
- H Shikama
- Medicinal Research Laboratory, Ishibara Sangyo Kaisha, Ltd., Shiga, Japan
| | | | | | | | | | | | | |
Collapse
|
11
|
Orosz P, Krüger A, Hubbe M, Rüschoff J, Von Hoegen P, Männel DN. Promotion of experimental liver metastasis by tumor necrosis factor. Int J Cancer 1995; 60:867-71. [PMID: 7896459 DOI: 10.1002/ijc.2910600624] [Citation(s) in RCA: 47] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Models for experimental metastasis were established to investigate the influence of rmTNF on tumor-colony formation in the liver. Highly metastatic lymphoma tumor cells were either injected i.v. or inoculated s.c. to form spontaneous metastases. In both systems, administration of rmTNF to the animals led to significant enhancement of the number of liver metastases in comparison with control groups. The number of metastatic tumor-cell colonies at an early stage of metastasis was increased, as well as the number of surface metastases in a late stage. Consequently, TNF-treated animals revealed a higher mortality. The optimal time for TNF to exert this metastasis-enhancing effect was found to be 7 days after tumor inoculation. In vitro adhesion of the lymphoma tumor cells to a mouse endothelioma cell line was strongly inhibited by monoclonal antibodies interfering with the interaction of VCAM-1 with VLA-4. These results support and extend earlier results with a fibrosarcoma lung colonization model. In addition, they show that stimulation of the immune system in tumor-bearing hosts activates tumor-promoting pathways, in addition to having possible beneficial effects.
Collapse
Affiliation(s)
- P Orosz
- German Cancer Research Centre, Division of Cellular Immunology, Heidelberg
| | | | | | | | | | | |
Collapse
|
12
|
Miyata K, Mitsuishi Y, Shikama H, Kuroda K, Nishimura K, Sakae N, Kato M. Overcoming the metastasis-enhancing potential of human tumor necrosis factor alpha by introducing the cell-adhesive Arg-Gly-Asp sequence. J Interferon Cytokine Res 1995; 15:161-9. [PMID: 8590320 DOI: 10.1089/jir.1995.15.161] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
A mutein, F4168, of human tumor necrosis factor alpha (hTNF-alpha) containing the cell-adhesive Arg-Gly-Asp (RGD) sequence near the N terminus was constructed. In contrast to hTNF-alpha, the mutein had binding activity to B16F10/L5 melanoma cells similar to that of fibronectin or laminin, indicating that the adhesive nature of the RGD sequence is conferred upon hTNF-alpha. Introduction of the RGD sequence did not alter the antitumor potential of hTNF-alpha. Simultaneous injection of F4168 and B16F10/L5 melanoma cells into mice did not enhance metastasis formation in lungs, whereas hTNF-alpha significantly promoted it. Enhancement of spontaneous lymph node metastasis of B16F10/L5 cells was also evident in TNF-alpha- but not in F4168-treated mice. In the spontaneous lymph node metastasis model of MethA fibrosarcoma, F4168 injection inhibited metastasis formation more effectively than hTNF-alpha. B16F10/L5 melanoma cells treated with hTNF-alpha enhanced not only their binding activity to laminin but also their invasive potential into Matrigel, whereas F4168 showed no such enhancement. These results suggest that F4168 is a low-toxicity mutein of hTNF-alpha.
Collapse
Affiliation(s)
- K Miyata
- Medicinal Research Laboratory, Ishihara Sangyo Kaisha, Ltd., Shiga, Japan
| | | | | | | | | | | | | |
Collapse
|
13
|
Kawashima A, Nakanishi I, Tsuchiya H, Roessner A, Obata K, Okada Y. Expression of matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) induced by tumour necrosis factor alpha correlates with metastatic ability in a human osteosarcoma cell line. Virchows Arch 1994; 424:547-52. [PMID: 8032535 DOI: 10.1007/bf00191442] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
We have examined the correlation between matrix metalloproteinase (MMP) expression and metastatic properties of a low metastatic osteosarcoma cell line, osteosarcoma takase (OST), under stimulation by tumour necrosis factor alpha (TNF alpha). In vivo, OST cells exhibited significantly increased colonization in the lungs of nude mice in a dose-dependent manner when they were treated by TNF alpha prior to injection. In vitro, TNF alpha enhanced tumour cell invasion through the reconstituted basement membrane in a transwell chamber up to 2.5-fold. Gelatin zymography and sandwich enzyme immunoassays demonstrated marked production of MMP-9 [92-kDa gelatinase/type IV collagenase (gelatinase B)] but not MMP-2 [72-kDa gelatinase/type IV collagenase (gelatinase A)], MMP-3 (stromelysin-1) or MMP-7 (matrilysin). Motility of the tumour cells and adhesion to cultured endothelial cells were slightly increased by the TNF alpha treatment up to 1.6-fold and 1.4-fold, respectively, while the growth rate was decreased. These results suggest that upregulation of MMP-9 together with enhanced motility and endothelial adhesion contribute to the increased metastatic ability of OST cells induced by TNF alpha treatment.
Collapse
Affiliation(s)
- A Kawashima
- Department of Pathology, School of Medicine, Kanazawa University, Ishikawa, Japan
| | | | | | | | | | | |
Collapse
|
14
|
Männel DN, Rüschoff J, Orosz P. The role of TNF in tumour growth and metastasis. RESEARCH IN IMMUNOLOGY 1993; 144:364-9. [PMID: 8278659 DOI: 10.1016/s0923-2494(93)80081-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Affiliation(s)
- D N Männel
- Dept. of Pathology, University of Regensburg, Germany
| | | | | |
Collapse
|
15
|
Orosz P, Echtenacher B, Falk W, Rüschoff J, Weber D, Männel DN. Enhancement of experimental metastasis by tumor necrosis factor. J Exp Med 1993; 177:1391-8. [PMID: 8478614 PMCID: PMC2191015 DOI: 10.1084/jem.177.5.1391] [Citation(s) in RCA: 142] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
The influence of endogenous and exogenous tumor necrosis factor (TNF) on metastasis was investigated in an experimental fibrosarcoma metastasis model. A single intraperitoneal injection of recombinant human (rh) TNF or recombinant mouse (rm) TNF into mice 5 h before intravenous inoculation of methylcholanthrene-induced fibrosarcoma cells (CFS1) induced a significant enhancement of the number of metastases in the lung. Dose responses of rmTNF and rhTNF demonstrated a stronger metastasis-augmenting effect by rmTNF compared with rhTNF. This effect was time dependent, as administration of rmTNF 5 h before or 1 h but not 24 h after tumor cell inoculation caused an increase of tumor cell colony formation on the lung surface, suggesting an influence of TNF on the vascular adhesion and diapedesis of tumor cells. Since tumor-bearing mice showed an enhanced ability to produce TNF after endotoxin injection compared to control mice, tumor-bearing mice were treated with anti-mTNF antibodies. Neutralization of endogenous tumor-induced TNF led to a significant decrease of the number of pulmonary metastases. Histological analysis of micrometastases in the lung on day 5 by silver staining of proteins associated with nucleolar organizer regions revealed more metastatic foci and augmented proliferative activity of the tumor cells after rmTNF pretreatment of mice. However, no direct effect of rmTNF on the proliferation rate of tumor cells was seen in vitro. These findings suggest that low doses of endogenous TNF or administered TNF during cytokine therapy might enhance the metastatic potential of circulating tumor cells.
Collapse
Affiliation(s)
- P Orosz
- Institute for Immunology and Genetics, German Cancer Research Center, Heidelberg
| | | | | | | | | | | |
Collapse
|